Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
Phase 1
Not yet recruiting
- Conditions
- Advanced Solid TumorMetastatic Solid TumorEndometrial CancerMSI-H CancerColorectal CancerGastric CancerdMMR Cancer
- Interventions
- First Posted Date
- 2025-05-15
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- MOMA Therapeutics
- Target Recruit Count
- 132
- Registration Number
- NCT06974110
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
Phase 1
Recruiting
- Conditions
- Advanced Solid TumorMetastatic Solid TumorProstate CancerPancreas CancerOvarian CancerBreast CancerHomologous Recombination Deficiency
- Interventions
- First Posted Date
- 2024-08-09
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- MOMA Therapeutics
- Target Recruit Count
- 158
- Registration Number
- NCT06545942
- Locations
- 🇺🇸
Investigative Site #109, Philadelphia, Pennsylvania, United States
🇪🇸Investigative Site #114, Barcelona, Spain
🇪🇸Investigative Site #115, Madrid, Spain